- Lonza reported FY 2025 sales of CHF 6.5 billion, with CER sales growth of 21.7% and a CORE EBITDA margin of 31.6%.
- The company expects continued growth in 2026, forecasting CER sales growth of 11–12% and further margin expansion.
Lonza reported sales of CHF 6.5 billion in FY 2025, representing CER sales growth of 21.7% compared with the prior year. CORE EBITDA reached CHF 2.1 billion, resulting in a margin of 31.6%, supported by maturing growth projects, operational execution, and operating leverage. Excluding the business related to the Vacaville site, organic CER sales growth was in the low-teens, in line with the company’s CDMO Organic Growth Model.
Sales performance in 2025 was driven by strong momentum across Mammalian, Bioconjugates, Small Molecules, Drug Product, and Bioscience Technology Platforms. The contribution from the Vacaville site exceeded expectations, while performance in Cell and Gene Therapy was softer and Microbial showed phasing effects. The company also reported strong order momentum, including an increasing number of integrated drug substance–drug product agreements for clinical and commercial programs.
During the year, Lonza implemented a simplified operating model under its One Lonza strategy, organizing the business into three platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. The company also established a group-wide Strategic Enterprise Account Management team and a new corporate strategy, innovation, and M&A function, while continuing progress on the carve-out and exit of its CHI business.
Capital expenditure totaled CHF 1.3 billion in 2025, representing 19.6% of sales, as Lonza advanced organic investment programs across Mammalian, Drug Product, Bioconjugates, and Cell and Gene Therapy. The Vacaville large-scale mammalian drug substance facility was fully integrated into Lonza’s global manufacturing network, securing additional commercial contracts and completing its first FDA audit under Lonza ownership.
“2025 was a strong year for the One Lonza team, marked by significant revenue growth with expanding profitability alongside tangible progress on our transformation journey.”
Wolfgang Wienand, Chief Executive Officer of Lonza
For 2026, the company expects CER sales growth of 11–12%, CORE EBITDA margin expansion to above 32%, and continued demand for CDMO and contract manufacturing services across its global network.
